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Abstract 
Clostridium difficile is a Gram-positive obligate anaerobic bacterium that recognized an important 
pathogen of humans. The present study aimed to evaluate the intestinal level of neutrophil gelatinase-
associated lipocalin (NGAL) in patients with C. difficile infection (CDI) as a disease activity marker in 
the south of Iran. This cross-sectional study conducted from October 2017 to June 2018 on patients 
referred to Nemazee and Amir Hospital in Shiraz, South of Iran. Patients less than two years old were 
excluded from the study. The study population was consist of 46 cases (Symptomatic patients that 
confirmed as a CDI), and 21 control individuals (Asymptomatic patients colonized by C. difficile). C. 
difficile isolates were identified by conventional microbiological producers and amplification of 
housekeeping gene by PCR method. The level of NGAL was determined by enzyme-linked 
immunosorbent assay (ELISA) according to the instructions of the kit manufacturer. The results 
showed that the level of NGAL in symptomatic patients' (case group) was higher than asymptomatic 
carriers (control group), 5.9 ng/mL vs. 4.1 ng/mL; however the observed difference was not statistically 
significant. Also, in both groups, the mean level of NGAL was significantly higher in patients with 
gastrointestinal diseases than others.  In summary, despite all the limitations, the results of the present 
study indicate that the intestinal level of NGAL is a biological indicator of intestinal inflammation, 
regardless of CDI. However, further study needs to elucidate the role of NGAL in inflammation caused 
by bacterial infections. 
Keywords: Clostridium difficile; CDI; Lipocalin-2; NGAL; Gastrointestinal diseases  
 
1. Introduction 
Clostridium difficile is a Gram-positive obligate 
anaerobic bacterium that recognized an important 
pathogen of humans. The organism can cause serious 
diseases such as pseudomembranous colitis (PMC), 
toxic megacolon, and perforation of the colon [1, 2]. C. 
difficile is responsible for the majority of cases of 
nosocomial diarrhea [3]. Due to spore production, 
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they are often highly resistant to sterilizations and 
disinfectants which become them a successful 
healthcare-associated pathogen [4]. 
Neutrophil gelatinase-associated lipocalin 
(NGAL) also known as Lipocalin-2 (LCN2) belongs to 
a family of small secretory proteins that are expressed 
by different types of cells, the richest source of which is 
neutrophils [5, 6]. The results of experiments show a 
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systematic increase in the expression level of LCN2 in 
various models of colitis, including human 
inflammatory bowel diseases (IBD) [7]. Besides, 
human lipocalin has been reported to be increased in 
patients with ulcerative colitis [7]. Recently, it has been 
shown that LCN2 is a real-time indicator for kidney 
disease and meets all the criteria required for a 
biomarker [8]. Expression of LCN2 in adipose tissue 
has been increased in various experimental models of 
obesity and obese individuals, indicating that LCN2 
may be involved in inflammatory disorders [7]. 
Chassaing et al. introduced the LCN2 in the stool as an 
indicator to identify inflammation caused by 
inflammatory bowel disease, which could be linked to 
various intestinal infections and used as a biomarker 
index [7, 9]. 
The present study aimed to evaluate the intestinal 
level of NGAL in patients with C. difficile infection 
(CDI) as a disease activity marker in the south of Iran. 
2. Materials and Methods 
2.1. Study design 
This cross-sectional study conducted from 
October 2017 to June 2018 on patients referred to 
Nemazee and Amir Hospital in Shiraz, South of Iran. 
Patients less than two years old were excluded from 
the study. The study population was consist of 46 cases 
(Symptomatic patients that confirmed as a CDI), and 
21 control individuals (Asymptomatic patients 
colonized by C. difficile). C. difficile were identified by 
conventional microbiological producers including 
characteristics on cycloserine-cefoxitin fructose agar 
(CCFA) (MAST Diagnostic, UK) and amplification of 
triose phosphate isomerase (tpi) housekeeping gene 
by PCR method [10, 11]. This study was following the 
declaration of Helsinki and ethical permission was 
sought from the institutional Ethics Committee of 
Shiraz University of Medical Sciences (Approval No. 
IR.SUMS.REC.1396.S872). 
2.2. Measurement of NGAL level 
The level of NGAL was determined by enzyme-
linked immunosorbent assay (ELISA) according to the 
instructions of the Lipocalin-2/NGAL Human ELISA 
kit manufacturer with a detection limit of 0.02 ng/mL 
(BioVendor, Czech Republic). The samples were 
diluted to a ratio of 1:10 according to the kit protocol 
and previous studies in this field. After performing the 
ELISA test preparation steps, the Optical density of 
each well was read with an ELISA reader at a 
wavelength of 450 nm and the results were reported in 
ng/mL. The final result was calculated by multiplying 
the dilution coefficient at the concentration reported 
by the device. 
2.3. Statistical analysis 
The analysis was performed by using SPSSTM 
software, version 21.0 (IBM Co., Armonk, NY, USA). 
The results are presented as descriptive statistics in 
terms of relative frequency. Values were expressed as 
the mean ± standard deviation (continuous variables) 
or percentages of the group (categorical variables). 
The paired t-tests were used to compare means, and a 
P value <0.05 was considered as statistically 
significant. 
3. Results 
Totally, 46 symptomatic cases consist of 52.2% 
males and 47.8% females with a mean age of 
31.4±24.6 year, and 21 asymptomatic controls consist 
of 52.4% males and 47.6% females with a mean age of 
43.1±23.1 year were included. The distribution of 
underlying diseases are shown in Table 1. 
The results showed that the level of LCN2 in 
symptomatic patients' (case group) was higher than 
asymptomatic carriers (control group), 5.9 ng/mL vs. 
4.1 ng/mL; however the observed difference was not 
statistically significant (Figure 1).  
To determine the relationship between NGAL 
levels and gastrointestinal diseases, the mean level of 
NGAL in symptomatic patients with ulcerative colitis, 
gastroenteritis, colorectal cancer, and Crohn's was 
compared with the patients with non-gastrointestinal 
diseases. As shown in Figure 2, the mean level of 
NGAL was significantly higher in patients with 
gastrointestinal diseases than others (12.6 ng/mL vs. 
3.0 ng/mL; P <0.001). 
Also, in asymptomatic carriers (Figure 3), the 
mean level of NGAL was significantly higher in 
patients with gastrointestinal diseases than in others 
(8.1 ng/mL vs. 2.0 ng/mL; P <0.009). 
4. Discussion  
In recent years, the prevalence of CDI has 
increased significantly and has become a growing 
health concern, especially in hospitals [12]. Hospital-
acquired CDI can be a consequence of the 
development of the disease due to colonization with C. 
difficile or exposure to a new strain transmitted from 
patients or the environment [13].
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  Table 1. The distribution of underlying diseases among studied patients 
 
Underlying disease 
Case (symptomatic) Control (asymptomatic) 
Frequency Percent Frequency Percent 
Ulcerative colitis (UC) 8 17.4 1 4.8 
Acute lymphoblastic leukemia (ALL) 5 10.9 2 9.5 
Liver transplantation 5 10.9 3 14.3 
Gastroenteritis 5 10.9 4 19.0 
Acute myeloid leukemia (AML)  1 2.2 - - 
Kidney failure 4 8.7 2 9.5 
Diabetes mellitus (DM) 2 4.3 - - 
Metabolic disorder  2 4.3 - - 
Pneumonia  2 4.3 - - 
Autoimmune hepatitis 1 2.2 - - 
Chronic lymphocytic leukemia (CLL) 1 2.2 1 4.8 
Colon Cancer 1 2.2 - - 
Crohn's 1 2.2 1 4.8 
Glaucoma  1 2.2 - - 
Liver neoplasms 1 2.2 - - 
Multiple myeloma 1 2.2 - - 
Myelodysplastic syndromes (MDS) 1 2.2  - 
Non-Hodgkin lymphoma (NHL) 1 2.2 - - 
Optic Glioma 1 2.2 -  
Osteosarcoma 1 2.2 - - 
Wilm's Tumor 1 2.2 - - 
Chronic myelogenous leukemia (CML) - - 2 9.5 
Aspiration pneumonia - - 1 4.8 
GI vasculitis - - 1 4.8 
Guillain-Barre - - 1 4.8 
Kidney transplantation - - 1 4.8 
Mushroom poisoning - - 1 4.8 
Total 46 100 21 100 
 
 
Figure 1. Comparison the intestinal level of NGAL in case 
(symptomatic) and control (asymptomatic carriers) groups 
 
Figure 2: Comparison the intestinal level of NGAL in patients with 
gastrointestinal diseases and other patients among the case group 
(symptomatic) 
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In a study by Chassaing et al., suggested that the 
LCN2 in feces can be an indicator for the identification 
of inflammation caused by IBD in mouse models. Also, 
they suggest that LCN2 could be linked to other 
intestinal infections, but to introduce as a biomarker 
needs to future examination [7]. 
In the present study, there was no statistically 
significant difference between the levels of LCN2 
among case and control groups. However, the 
intestinal level of LCN2 in both groups was 
significantly higher in people with gastrointestinal 
diseases. Previously, Xiu Guo et al. had shown that in 
infected animal models with pathogenic strains of 
Escherichia coli, the level of LCN2 in the jejunum 
increased rapidly [14]. These results indicate that 
LCN2 as a proinflammatory factor can be expressed 
independently of the presence of bacterial infection, 
but the presence of any intestinal inflammation can 
significantly promote its production. It has been 
suggested that alteration in the level of LCN2 can 
balance the level of the intestinal microbiome and the 
host response to infection [7, 15]. It has also been 
shown that increasing LCN2 levels helps to limit 
infection by inhibiting siderophore receptors and 
reducing pathogen access to iron [14]. 
The main limitations including the fact that the 
present study is a cross-sectional study that was 
performed only on patients with antibiotic-related 
diarrhea and not all diarrhea patients were tested for 
the presence of C. difficile. 
In summary, despite all the limitations, the results 
of the present study indicate that the intestinal level of 
NGAL is a biological indicator of intestinal 
inflammation, regardless of CDI. However, further 
study need to elucidate the role of NGAL in 
inflammation caused by bacterial infections. 
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